Committee for Medicinal Products for Human Use (CHMP) assess d the medicine to reach its opinion in favour of granting a marketing authorisation and its recomme dations on the conditions of use for Fablyn.
Fablyn is used for the treatment of osteoporosis (a disease that makes bones fragile) in
elsewhere in the body, but not in the hip.
postmenopausalMedicinalwomen (women who have been through the menopause). It is used in women who are at risk of fracture (broken bones). Fablyn has been shown to reduce fractures in the spine and
When decid ng whether to prescribe Fablyn or other treatments, doctors should consider whether the patient has any symptoms of the menopause, and the possible effects of treatment on the womb, the breast, and the heart and blood vessels.
The medicine can only be obtained with a prescription.